1. Department of Leukemia, MD Anderson Cancer Center Houston, TX;
2. Centre for Haematology, Imperial College London, United Kingdom;
3. Clinical Onco-Hematology Department, Almazov National Medical Research Centre, St Petersburg, Russia;
4. Department of Hematology/Oncology, Hospital Jose Maria Ramos Mejia, Buenos Aires, Argentina;
5. Department of Naematology, Hospital del Salvador, Santiago, Chile;
6. Research Department, Fundaleu, Buenos Aires, Argentina;
7. Department of Clinical Translational Research, Singapore General Hospital, Duke-National University of Singapore (NUS) Medical School, Singapore;
8. Department of Haematology, Jagiellonian University Hospital in Krakow, Krakow, Poland;
9. Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada;
10. Department of Hematology-Oncology, Karmanos Cancer Center at Wayne State University, Detroit, MI;
11. Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, The John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ;
12. Department of Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany;
13. Department of Hematology/Oncology, Hospital Mignot University de Versailles Saint-Quentin-en-Yvelines, Paris, France;
14. Department of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy;
15. Department of Haematological Medicine, King's College Hospital, National Health Service (NHS) Foundation, London, United Kingdom;
16. Scientific and Consultative Department of Myeloproliferative Diseases, National Research Centre for Haematology, Moscow, Russia;
17. Department of Haematology, Centro de Investigaciones Clinicas Vina del Mar, Valparaíso, Chile;
18. Department of Haematology, Royal North Shore Hospital, St Leonards, NSW, Australia;
19. Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE;
20. Department of Hematology/Oncology, Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI;
21. Myeloproliferative Neoplasms (MPN) Program, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY;
22. Pharmacovigilence Department, Millennium Pharmaceuticals, Inc, Cambridge, MA;
23. Oncology Statistics Department, Millennium Pharmaceuticals, Inc, Cambridge, MA;
24. Clinical Science Department, Millennium Pharmaceuticals, Inc, Cambridge, MA; and
25. Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT